Academic institution
Appears in 1 story
Co-led the OBERON and TITANIA trials
Millions of COPD patients who don't respond to current biologic treatments may soon have a new option. AstraZeneca's tozorakimab cut moderate-to-severe flare-ups by 29% to 34% in two late-stage trials, and unlike existing biologics, it worked across all blood eosinophil levels.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
